β-Adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study

Pasco, Julie A., Henry, Margaret J., Sanders, Kerrie M., Kotowicz, Mark A., Seeman, Ego and Nicholson, Geoffrey C. (2004) β-Adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study. Journal of Bone and Mineral Research, 19 1: 19-24. doi:10.1359/JBMR.0301214


Author Pasco, Julie A.
Henry, Margaret J.
Sanders, Kerrie M.
Kotowicz, Mark A.
Seeman, Ego
Nicholson, Geoffrey C.
Title β-Adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study
Journal name Journal of Bone and Mineral Research   Check publisher's open access policy
ISSN 0884-0431
1523-4681
Publication date 2004-01
Sub-type Article (original research)
DOI 10.1359/JBMR.0301214
Volume 19
Issue 1
Start page 19
End page 24
Total pages 6
Place of publication Malden, MA, United States
Publisher Wiley-Blackwell
Language eng
Formatted abstract
This population-based study documented β-blocker use in 59/569 cases with incident fracture and 112/775 controls. OR for fracture associated with β-blocker use was 0.68 (95% CI, 0.49-0.96). β-Blockers were associated with higher BMD at the total hip (2.5%) and UD forearm (3.6%) after adjusting for age, anthropometry, and thiazide use. β-Blocker use is associated with reduced fracture risk and higher BMD. Introduction: Animal data suggests that bone formation is under β-adrenergic control and that β-blockers stimulate bone formation and/or inhibit bone resorption. Materials and Methods: We evaluated the association between β-blocker use, bone mineral density (BMD), and fracture risk in a population-based study in Geelong, a southeastern Australian city with a single teaching hospital and two radiological centers providing complete fracture ascertainment for the region. β-Blocker use was documented for 569 women with radiologically confirmed incident fractures and 775 controls without incident fracture. Medication use and lifestyle factors were documented by questionnaire. Results: Odds ratio for fracture associated with β-blocker use was 0.68 (95% CI, 0.49-0.96) for any fracture. Adjusting for age, weight, medications, and lifestyle factors had little effect on the odds ratio. β-Blocker use was associated with a higher BMD at the total hip (2.5%, p = 0.03) and ultradistal forearm (3.6%, p = 0.04) after adjustment for age, anthropometry, and thiazide use. Conclusion: β-Blockers are associated with a reduction in fracture risk and higher BMD.
Keyword Beta-blocker
Fracture
Bone densitometry
Population studies
Case-control studies
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 156 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 181 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 24 May 2011, 14:53:03 EST by System User on behalf of Rural Clinical School